The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer

JOURNAL ARTICLE published December 2008 in BJU International

Authors: Laurence Klotz | Laurent Boccon‐Gibod | Neal D. Shore | Cal Andreou | Bo‐Eric Persson | Per Cantor | Jens‐Kristian Jensen | Tine Kold Olesen | Fritz H. Schröder